新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 阿斯利康 » 阿斯利康与KI联合成立心血管代谢疾病研究中心

阿斯利康与KI联合成立心血管代谢疾病研究中心

来源:生物谷 2013-07-03 16:46

2013年7月3日讯 /生物谷BIOON/ --阿斯利康(AstraZeneca)7月1日宣布,与世界顶尖学术机构——瑞典卡罗林斯卡医学院(Karolinska Institutet,KI)达成了有史以来最大规模合作,双方将联手成立一个心血管和代谢疾病研究中心——卡罗林斯卡/阿斯利康综合心血管代谢中心(Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre)。

该中心将容纳6个研究组,来自双方的20-30名科学家将在该中心全职工作,同时阿斯利康将在今后的5年内提供1亿美元的研究资金。

阿斯利康称,该中心的目的是利用小分子和生物制剂鉴别及验证心血管代谢疾病领域的新靶标,重点为心肌再生和糖尿病肾病。

过去,阿斯利康一直在与学术机构进行广泛的合作。但此次与卡罗林斯卡医学院的合作,首次充分整合了双方的研究团队,将加速推进突破性研究向新药开发的进程,并提高阿斯利康在心血管和代谢疾病研究中的科学领导地位。(生物谷Boon.com)

英文原文:AstraZeneca, Karolinska Institutet to Launch $100M Cardiovascular, Metabolic Disease Center

Jul 1, 2013 In the drugmaker’s largest-ever collaboration with a Swedish academic institution, AstraZeneca is teaming up with Karolinska Institutet to establish a cardiovascular and metabolic disease research center.

The phama giant will contribute up to $100 million over five years to the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre, in which scientists from both organizations will work under the same director, for which recruitment is underway. All told, the center will house up to six research groups involving 20 to 30 scientists from both organizations, who will become full-time employees at the center.

AstraZeneca and Karolinska said the center’s aim is to identify and validate novel targets within cardiometabolic diseases, with particular focus on cardiac regeneration and diabetic nephropathy via small molecules and biologics.

In a statement, Stockholm-Uppsala Life Science said the establishment of this center is one of several “clear indicators that the sector is in robust health despite the recent closing of AstraZeneca’s neuroscience facility” in the region.

“We believe that this new collaboration model, with research groups located under one roof and working in a fully integrated manner will be prove a success for both industry and academia,” Karolinska president Anders Hamsten said in a statement.

Added Marcus Schindler, vp, head of CVMD iMed, AstraZeneca: “We have worked side by side with academic institutions in the past, but this is the first time that AstraZeneca will fully integrate our research teams with an academic institution. We believe that this will speed up the progression from groundbreaking research into the delivery of new medicines and advance our scientific leadership in cardiovascular and metabolic research.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库